SubsidieMeestersMenstrual blood multiomics analysis to better diagnose, understand and treat endometriosis
The MensEndoDiag project seeks to identify diagnostic and prognostic biomarkers for endometriosis using menstrual fluid, while exploring new therapeutic approaches to improve patient outcomes.
Projectdetails
Introduction
The MensEndoDiag project aims at finding diagnostic biomarkers and prognostic biomarker candidates, as well as investigating new therapeutic approaches for endometriosis using menstrual fluid, an easily accessible yet overlooked biological fluid.
Background
Endometriosis is a common gynecological disorder affecting 6-10% of women of childbearing age. It is associated with pelvic pain and infertility, leading to a reduced quality of life and an economic burden. It is defined by the presence of endometrial tissue outside the uterus. Endometriotic lesions form from retrograde menstruation (menstrual fluid reflux through the fallopian tubes), but the precise pathogenesis remains unclear.
Current Challenges
There are no noninvasive biomarkers currently used in clinical care, but they are essential to improve the diagnosis delay, currently estimated at 8 years. There is no specific treatment, and pharmacological options are contraceptive. Here, I propose to use menstrual fluid as a relevant biological fluid for endometriosis.
Project Aims
-
Aim 1: Single-cell transcriptomics and soluble protein multiplex assays on 64 menstrual fluid samples will be used to identify candidate diagnostic biomarkers that differentiate endometriosis-affected women from healthy controls. Validation of these biomarkers will be carried out in menstrual fluid samples from 250 women.
-
Aim 2: Menstrual fluid-derived organoids cultured with or without immune cells will be used to assess endometriosis-associated functional changes and to test new immunomodulatory treatments.
-
Aim 3: Longitudinal cohorts will be established to identify prognostic candidate biomarkers for response to surgery and in vitro fertilization.
Importance of the Project
Diagnostic and prognostic biomarkers are essential to assess disease establishment, evolution, and to choose the most appropriate treatment. This project will enhance our understanding of endometriosis pathophysiology as well as allow the study of a new biological fluid, relevant to gynecologic and reproductive disorders.
Financiële details & Tijdlijn
Financiële details
| Subsidiebedrag | € 1.479.399 |
| Totale projectbegroting | € 1.479.399 |
Tijdlijn
| Startdatum | 1-5-2023 |
| Einddatum | 30-4-2028 |
| Subsidiejaar | 2023 |
Partners & Locaties
Projectpartners
- UNIVERSITE PARIS CITEpenvoerder
- INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE
Land(en)
Vergelijkbare projecten binnen European Research Council
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
Hormone-microbiome interactions as a key-player in female healthThis project aims to investigate hormone-microbiome interactions in women to understand their impact on health and infertility, ultimately identifying biomarkers and new therapeutic strategies. | ERC Starting... | € 1.499.485 | 2022 | Details |
Deciphering female’s SEx hormones - MIcrobiota interactions during a menstrual CYCLE for an efficient personalized medicine in cardiometabolic disordersThe SEMICYCLE project aims to identify female-specific microbiota features influencing glycaemic and lipid metabolism to improve prevention and treatment strategies for cardiometabolic disorders in women. | ERC Starting... | € 1.499.286 | 2023 | Details |
Epigenetic profiling of menstrual blood for precision cancer detection and preventionThe EpiPrecise project aims to refine a cellular deconvolution algorithm for developing novel epigenetic tests to improve cancer detection and prevention strategies, particularly for women's cancers. | ERC Proof of... | € 150.000 | 2024 | Details |
Unveiling the Molecular Secrets of Reproductive Mood Disorders: a Multi-Omics Approach ProjectThe MoodMAP project aims to identify molecular markers and biological factors of reproductive mood disorders to improve diagnosis, prevention, and treatment strategies for women's mental health. | ERC Starting... | € 1.499.999 | 2025 | Details |
Detecting epigenetic biomarkers in the blood for non-invasive precision oncologyDevelop new non-invasive diagnostic methods for cancer by analyzing epigenetic markers in circulating tumor DNA to improve sensitivity and monitor disease evolution. | ERC Starting... | € 1.500.000 | 2022 | Details |
Hormone-microbiome interactions as a key-player in female health
This project aims to investigate hormone-microbiome interactions in women to understand their impact on health and infertility, ultimately identifying biomarkers and new therapeutic strategies.
Deciphering female’s SEx hormones - MIcrobiota interactions during a menstrual CYCLE for an efficient personalized medicine in cardiometabolic disorders
The SEMICYCLE project aims to identify female-specific microbiota features influencing glycaemic and lipid metabolism to improve prevention and treatment strategies for cardiometabolic disorders in women.
Epigenetic profiling of menstrual blood for precision cancer detection and prevention
The EpiPrecise project aims to refine a cellular deconvolution algorithm for developing novel epigenetic tests to improve cancer detection and prevention strategies, particularly for women's cancers.
Unveiling the Molecular Secrets of Reproductive Mood Disorders: a Multi-Omics Approach Project
The MoodMAP project aims to identify molecular markers and biological factors of reproductive mood disorders to improve diagnosis, prevention, and treatment strategies for women's mental health.
Detecting epigenetic biomarkers in the blood for non-invasive precision oncology
Develop new non-invasive diagnostic methods for cancer by analyzing epigenetic markers in circulating tumor DNA to improve sensitivity and monitor disease evolution.
Vergelijkbare projecten uit andere regelingen
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
She Sense: an accurate and non-invasive test that enables simpler, earlier and more cost-effective diagnosis of patients with endometriosisThe project aims to advance the She Sense test for non-invasive endometriosis diagnosis by optimizing its digital biomarker and validating it clinically for commercial readiness. | EIC Transition | € 2.499.166 | 2023 | Details |
WOMED: an innovative intrauterine biodegradable polymer-based drug-delivery platformWomed aims to revolutionize uterine disorder treatments with innovative local therapies, starting with a drug-free device for fertility and developing solutions for fibroids and endometriosis pain. | EIC Accelerator | € 2.493.809 | 2024 | Details |
Mid-infrared Wearable for Non-invasive biomarker monitoringThe project aims to develop a wearable device using a miniature Mid-Infrared spectrometer for non-invasive biomarker detection in metabolic syndrome, enhancing early diagnosis and management. | EIC Pathfinder | € 3.991.297 | 2024 | Details |
Commercialisation and scale up of a Vaginal Microbiome Screening service with a menstrual tampon collection device and a digital layer to provide diagnosis, disease risk evaluation and aftercare.VMS is a home-based gynaecological test kit that uses tampons for accurate STI and HPV screening, offering comprehensive aftercare and insights into vaginal health. | EIC Accelerator | € 2.499.999 | 2023 | Details |
Understanding the potential of modulating Host-Microbiome-Glycan interactions (“the triangle of sweetness”) to tackle non-communicable diseasesThe project aims to identify novel glycosyltransferases and HMOs, analyze their gut interactions, and validate an HMO for inflammation relief, enhancing glycobiology research and therapeutic applications. | EIC Pathfinder | € 3.920.718 | 2024 | Details |
She Sense: an accurate and non-invasive test that enables simpler, earlier and more cost-effective diagnosis of patients with endometriosis
The project aims to advance the She Sense test for non-invasive endometriosis diagnosis by optimizing its digital biomarker and validating it clinically for commercial readiness.
WOMED: an innovative intrauterine biodegradable polymer-based drug-delivery platform
Womed aims to revolutionize uterine disorder treatments with innovative local therapies, starting with a drug-free device for fertility and developing solutions for fibroids and endometriosis pain.
Mid-infrared Wearable for Non-invasive biomarker monitoring
The project aims to develop a wearable device using a miniature Mid-Infrared spectrometer for non-invasive biomarker detection in metabolic syndrome, enhancing early diagnosis and management.
Commercialisation and scale up of a Vaginal Microbiome Screening service with a menstrual tampon collection device and a digital layer to provide diagnosis, disease risk evaluation and aftercare.
VMS is a home-based gynaecological test kit that uses tampons for accurate STI and HPV screening, offering comprehensive aftercare and insights into vaginal health.
Understanding the potential of modulating Host-Microbiome-Glycan interactions (“the triangle of sweetness”) to tackle non-communicable diseases
The project aims to identify novel glycosyltransferases and HMOs, analyze their gut interactions, and validate an HMO for inflammation relief, enhancing glycobiology research and therapeutic applications.